Iradimed Co (IRMD)

Name: Iradimed Co (IRMD) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Iradimed Co (IRMD)

Stock Card

$87.07

$0.07 (0.08%)

As on 28-Aug-2026 16:00EDT

Market cap

$1,113 Mln

Revenue (TTM)

$86 Mln

P/E Ratio

48.6

P/B Ratio

10.9

Div. Yield

0.9 %

Iradimed Co (IRMD) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 86.43 High: 88.40

52 Week Range

Low: 67.84 High: 107.90

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.2 %
ROCE

-- %
Industry P/E

44.46
EV/EBITDA

36.4
Debt to Equity

0
Book Value

$8
EPS

$1.8
Face value

--
Shares outstanding

12,786,991

10 Years Aggregate

CFO

$81.25 Mln

EBITDA

$93.85 Mln

Net Profit

$73.94 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Iradimed Co (IRMD)	-10.5	-8.4	-5.2	17.9	22.5	20.9	16.9
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Iradimed Co (IRMD)	76.9	15.7	67.8	-37.5	102.7	-2.5	-4.4
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Iradimed Co (IRMD)	87.1	1,113.4	86.3	23.1	33.9	23.5	48.6	10.9
10X Genomics Inc (TXG)	61.5	8,018.1	616.9	-75.1	1.7	-9.3	--	10.2
Avantor (AVTR)	14.6	9,638.1	6,561.1	-578.0	-4.5	-10.3	--	1.7
Bio-Rad Laboratories	365.1	9,761.6	2,589.3	222.4	-6.0	3	44.5	1.3
Bruker (BRKR)	57.1	8,696.7	3,499.6	-71.2	0.5	-3.2	--	3.8
Glaukos Corp (GKOS)	179.9	10,905.5	612.8	-188.1	-30.6	-28.1	--	16.4
Lantheus Holdings (LNTH)	100.8	6,577.5	1,556.3	275.3	24.6	22.9	24.1	5.0
Merit Medical Systems (MMSI)	90.5	5,403.2	1,579.2	145.6	14.3	8.9	37.2	3.2
Penumbra (PEN)	321.7	12,752.7	1,504.9	160.6	13.6	10.9	79.4	8.4
Repligen (RGEN)	176.3	9,947.9	785.1	41.5	9.9	2	251.8	4.9

Shareholding Pattern

View Details

About Iradimed Co (IRMD)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers... MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida. Read more

Founder, Chairman, CEO & President

Mr. Roger E. Susi
Founder, Chairman, CEO & President

Mr. Roger E. Susi
Headquarters

Orlando, FL
Website

https://www.iradimed.com

FAQs for Iradimed Co (IRMD)

What is the current share price of Iradimed Co (IRMD) Today?

The share price of Iradimed Co (IRMD) is $87.07 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Iradimed Co (IRMD) has given a return of 22.53% in the last 3 years.

What is the current PB & PE ratio of Iradimed Co (IRMD)?

The P/E ratio of Iradimed Co (IRMD) is 48.64 times as on 28-Aug-2026, a 9 premium to its peers’ median range of 44.46 times.
The P/B ratio of Iradimed Co (IRMD) is 10.93 times as on 28-Aug-2026, a 188 premium to its peers’ median range of 3.79 times.

PE & PB ratio at the end of financial year.